Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1

Conditions

Hematologic Neoplasms 2Multiple Myeloma 1

Interventions

talquetamab 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ivosidenib 1ipatasertib 1fedratinib 1erdafitinib 1enasidenib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Hematologic Neoplasms × talquetamab × Clear all
NCT03399799 2026-06-05

MonumenTAL-1

Janssen Research & Development, LLC

Phase 1 Active not recruiting
279 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

NCT04634552 2026-06-05

MonumenTAL-1

Janssen Research & Development, LLC

Phase 2 Recruiting
510 enrolled 1 FDA
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡